Rethinking Long-term Beta-Blocker Use After Heart Attacks

For a long time, if you survived a heart attack, the standard advice was simple: stick with beta-blockers for life to safeguard your heart. Yet now, doctors are re-evaluating whether these medications are truly necessary beyond the initial recovery year.

Beta-blockers, widely prescribed, help in lowering blood pressure and managing heart rate, making them a go-to for many cardiovascular issues. While generally safe, they can come with side effects like fatigue, dizziness, and dry mouth, among others—so, it’s not all sunshine.

For more than 40 years, these medications have been standard for heart attack survivors, particularly those without complications, aiming to minimize future cardiovascular risks. Many continue on beta-blockers indefinitely. However, a growing pool of studies is beginning to challenge this longstanding practice.

Some physicians now propose that limiting beta-blocker use to just a year or two might be more beneficial, potentially avoiding unnecessary side effects and saving patients money.

The American Heart Association and the American College of Cardiology regularly update their guidelines on heart condition treatments. In 2023, they advised against long-term beta-blocker therapy for patients with chronic coronary disease who hadn’t experienced a heart attack in the previous year.

Dr. Manesh Patel, president-elect of the American Heart Association, mentions that the landscape is shifting. There’s growing evidence questioning the need for prolonged beta-blocker use post-heart attack.

“Originally, beta-blockers were utilized before we had many of today’s advanced treatments, like angioplasty and certain blood thinners,” Patel noted, reflecting on how medical technology has evolved since beta-blockers were first introduced.

New findings may encourage doctors to reconsider existing therapies. “It seems we have accumulating evidence suggesting that stable patients after a heart attack might not need to remain on beta-blockers indefinitely,” he said.

This evolving standard could significantly affect financial expenditure for heart attack survivors, according to Dr. Joseph Ravenell from NYU Langone Health. He emphasizes that if similar health benefits can be achieved without lifelong medication, so much the better for patients’ quality of life and finances.

Despite many beta-blockers being reasonably priced—roughly $20 for a month’s supply—over time, these costs can add up. “When you think about the long haul—those expenses really stack up,” he pointed out. It’s often the side effects or costs that lead to non-compliance with medication regimens, so any relief would be a win.

Already, some doctors are adapting their prescribing approaches for heart attack patients globally, as Dr. Valentin Fuster from Mount Sinai noted. Over the last decade or so, he and others have begun to question the efficacy of beta-blockers for those who exhibit good heart function.

He believes a broader change in practice is on the horizon. “It’s already starting with recent publications challenging their long-term use,” Fuster stated.

Recent studies, as highlighted in the New England Journal of Medicine, have shown that starting beta-blockers soon after a heart attack doesn’t significantly impact outcomes for patients with normal heart function. Nevertheless, many stable patients still take them long after their initial event. A lingering question is how safe it is to stop them.

A new study assessing low-risk adults who were stable for at least a year post-heart attack shows encouraging results. Participants who stopped their beta-blockers didn’t encounter higher risks of death, recurrent heart attack, or heart failure hospitalizations compared to those who continued the medication, findings presented at the American College of Cardiology’s annual meeting suggest.

Dr. Joo-Yong Hahn, the study’s lead author, raised an important clinical question: “In stable patients who feel well for years, is there a real need to continue beta-blockers endlessly?”

The research involved over 2,500 adults across 25 health centers in South Korea. Most participants had been on beta-blockers for at least a year and were generally in their sixties.

Half of them were advised to stop beta-blockers while the other half stayed on them. Researchers monitored each group for nearly three years to assess various health outcomes.

Ultimately, only 7.2% of those who ceased beta-blockers faced adverse outcomes compared to 9% in the continuation group.

“For stable, low-risk individuals who have been on beta-blockers for years, the evidence shows stopping the medication keeps them just as safe,” Hahn explained.

In terms of specific outcomes, mortality rates were pretty close: 2.4% for those who stopped, versus 3.4% for those who didn’t. Recurrent heart attacks showed similar patterns, as did hospitalization rates for heart failure.

While there was a slight uptick in heart rate and blood pressure among those who stopped taking beta-blockers, their systolic blood pressure remained below 130—considered within normal limits.

Researchers noted that since the study was specific to South Korea, further studies are required to see if these findings hold true in other regions, like the U.S.

The study also raises questions about when might be the best time to stop beta-blockers, as this could vary from patient to patient.

While it doesn’t advocate for a blanket cessation of beta-blockers after a year, Hahn believes this could reshape practices significantly. It supports the notion that for stable patients without heart failure or certain heart function issues, lifelong beta-blockers may not be essential. “Discontinuation should always include shared decision-making and careful monitoring, especially where side effects are a concern,” he concluded.